GGrantIndex
← Search

Leadership, Planning and Evaluation

$81,457P30FY2019CANIH

Rbhs -Cancer Institute Of New Jersey, New Brunswick NJ

Investigators

Linked publications, trials & patents

Trial NCT05639972Trial NCT05483491Trial NCT05296421Trial NCT04929015Trial NCT04920344Trial NCT04871516Trial NCT04751747Trial NCT04445844Trial NCT04294264Trial NCT04285268Trial NCT04253483Trial NCT04211259Trial NCT04179227Trial NCT04163952Trial NCT04146038Trial NCT04081688Trial NCT03902379Trial NCT03725449Trial NCT03677739Trial NCT03456843Trial NCT03448224Trial NCT03441321Trial NCT03428802Trial NCT03272633Trial NCT03257163Trial NCT03233555Trial NCT03229278Trial NCT03228147Trial NCT03112668Trial NCT03108911Trial NCT03102060Trial NCT03061175Trial NCT03028948Trial NCT02949284Trial NCT02885649Trial NCT02748564Trial NCT02699996Trial NCT02688517Trial NCT02688192Trial NCT02621398Trial NCT02526511Trial NCT02526498Trial NCT02458716Trial NCT02421575Trial NCT02420652Trial NCT02324621Trial NCT02324608Trial NCT02315196Trial NCT02295540Trial NCT02294617Trial NCT02250781Trial NCT02203604Trial NCT02203578Trial NCT02177838Trial NCT02144701Trial NCT02144675Trial NCT02105116Trial NCT01828476Trial NCT01694589Trial NCT01652014Trial NCT01649947Trial NCT01480154Trial NCT01417286Trial NCT01407562Trial NCT01303341Trial NCT01251172Trial NCT01032590Trial NCT01018836Trial NCT01009931Trial NCT01006369Trial NCT00996359Trial NCT00991315Trial NCT00966667Trial NCT00962845Trial NCT00946283Trial NCT00943709Trial NCT00939380Trial NCT00934895Trial NCT00909909Trial NCT00905918Trial NCT00900120Trial NCT00899808Trial NCT00899639Trial NCT00895115Trial NCT00891969Trial NCT00878657Trial NCT00866840Trial NCT00853125Trial NCT00813423Trial NCT00786682Trial NCT00770419Trial NCT00770055Trial NCT00769652Trial NCT00765765Trial NCT00749437Trial NCT00740805Trial NCT00728845Trial NCT00726596Trial NCT00669734Trial NCT00667901

Abstract

LEADERSHIP, PLANNING AND EVALUATION PROJECT SUMMARY/ABSTRACT The mission of the Rutgers Cancer Institute of New Jersey (CINJ) is to reduce the burden of cancer by advancing cancer research, prevention, screening, education and care for one of the nation?s most diverse and densely populated states, as well as the broader nation. To accomplish this mission, the CINJ Director, Steven K. Libutti, MD, works closely with the rest of the CINJ Senior Leadership team, which includes the Deputy Director (Eileen White), and Associate Directors for Clinical Research (Howard S. Hochster), Basic Research (Eileen White), Cancer Prevention, Control and Population Research (Sharon L. Manne), Translational Research (Shridar Ganesan), Consortium Research (Yibin Kang), Research and Education Affairs (Edmund C. Lattime), Administration and Planning (Linda L. Tanzer) and Community Outreach and Engagement (new, Manne interim). Implementation of a five-year Strategic Plan (2015-2020) was underway at the time of Libutti?s arrival in 2017; the plan was re-assessed modified to represent the new Director?s vision. The Internal Advisory Board (includes the Chancellor, Deans and other leaders at Rutgers and Princeton Universities) and the External Advisory Board reviewed these proposed modifications and provided critical input and guidance. This oversight and leadership structure proved its effectiveness with the transition to a new Director; the major goals of the strategic plan were affirmed, with significant and sustained progress made toward accomplishing them, and new initiatives important to the Director?s vision were seamlessly integrated. Despite the change in Directorship, senior leaders did not lose momentum and achieved important strategic accomplishments, including: restructured and enhanced precision medicine initiative; recruitment of a new Associate Director for Clinical Research; increased accruals to interventional studies; creation of an Office of Community Outreach and Engagement and launch of a search for an Associate Director to oversee these efforts; expansion of the Metabolomics shared resource (jointly managed with Princeton University) and launch of two new developing shared resources for Small Molecule Screening (with Princeton) and Immune Monitoring; expansion of educational programs and successful management of major statewide retreats and conferences; launch of a new colon and lung cancer screening initiative for underserved regions of CINJ?s catchment area; and enhancement and strengthening of the consortium with Princeton University through the creation and appointment of an Associate Director for Consortium Research.

View original record on NIH RePORTER →